- Crystalys gets $130M to take Sobi-rivaling gout drug to marketA San Diego biotech has raised an additional $130 million to get a gout drug that's already approved in Japan and China onto the US and European markets. Crystalys Therapeutics reeled in the Seri…Endpoints · 3d ago↗ source
- Crystalys nets $130M more to push gout drug through late-stage tests<figure><div><img src="https://imgproxy.divecdn.com/THeKNpwt2ETxP7Nf-ec1mU-DtgG84p4ktQEqFznWC1c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODUxMTEwNjQucG5n.…BioPharma Dive · 3d ago↗ source
- Summit reports two-year survival data for Western patients, though context lackingSummit Therapeutics unveiled additional follow-up data on its experimental cancer drug ivonescimab, and how its benefit compares between Asian and Western patients. But key context remains unknown.…